ClinicalTrials.gg
TerminatedNCT03897491Updated Jun 1, 2026

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

A Phase 2 interventional study of 5-aminolevulinic acid in Glioblastoma, sponsored by photonamic GmbH & Co. KG. Terminated at 3 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by photonamic GmbH & Co. KG (formerly part of medac GmbH) · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment activities of clinical trial sites.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing Aminolevulinic Acid in Glioblastoma — 2 open to participants now, 3 under way, none of them phase 3. Aminolevulinic Acid · Glioblastoma.

Enrollment
10th of 20
17 · median 17
Started
2021
with 1 other
Phase 2
9 of 20
none open now
Registered
13th of 20
by date

Among the 20 studies testing Aminolevulinic Acid in Glioblastoma, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 9 in phase 2, and was the 13th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

2 of the 20 studies testing Aminolevulinic Acid in Glioblastoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Aminolevulinic Acid in Glioblastoma, or all of them as a file.
02

Study summary

The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed supratentorial IDH wild-type glioblastoma.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven, newly diagnosed, supratentorial, unifocal, lobar located IDH wild-type glioblastoma according to the criteria of the 2016 WHO classification.
  • Not safely and/or not completely resectable, lobar located, unifocal, supratentorial IDH wild-type glioblastomas with a largest diameter ≤ 40 mm (largest diameter of the contrast enhanced tumor, as defined by enhanced T1 MRI sequences) are eligible in case of corresponding tumor board re-estimations.
  • Potentially completely resectable, lobar located, unifocal, supratentorial, IDH wild-type glioblastoma with a largest diameter ≤ 40 mm are eligible in case of both patient's informed preference in favour of iPDT and corresponding tumor board recommendations.
  • Age 18 - 70 years
  • Performance status (KPS) of ≥ 70 %
  • Minimal of 3 months.
  • Patients eligible for radiotherapy plus concomitant and chemotherapy with temozolomide: Adequate haematological function ( (ANC) > 1.5 x 109/L, count > 100 x 109/L, > 10 g/dL (may be transfused to maintain or exceed this level)).
  • (INR) or PT (secs) and activated partial thromboplastin time (aPTT) ≤ 1,5 times of the in the laboratory where it was measured.
  • Negative pregnancy test in fertile women
  • For female and male patients of : Willingness to apply highly effective (Pearl index \<1) during the entire study.

Such methods include :

  • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

    • oral
    • intravaginal
    • transdermal
  • progestogen-only hormonal contraception associated with inhibition of ovulation :

    • oral
    • injectable
    • implantable
  • intrauterine device (IUD)
  • intrauterine hormone-releasing system (IUS)
  • bilateral tubal occlusion
  • vasectomised partner
  • sexual abstinence • Written has been signed and dated prior to or at the beginning of Visit -1

Exclusion criteria

Exclusion criteria:

  • Glioblastomas involving the basal ganglia, the corpus callosum, the primary motor cortex, the ventricular system, multifocal tumors, and those involving the brain stem and/or the cerebellum.
  • Glioblastomas exceeding the 40 mm threshold in their largest diameter
  • Simultaneous use of other potentially phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts)
  • against porphyrins
  • Known diagnosis of porphyria
  • Acute or chronic hepatic diseases (levels of ASAT, ALAT and/or gamma-GT more than 2.5 times the in the laboratory where it was measured)
  • Manifest renal diseases with renal dysfunction (serum creatinine level > 1.5 times of the upper limit of normal in the laboratory where it was measured)
  • Severe, active co-morbidity:
  • Unstable angina and/or congestive heart failure within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • History of stroke, cerebral vascular accident, or within 6 months
  • Serious and inadequately controlled cardiac arrhythmia
  • Significant vascular disease (e.g. aortic aneurysm)
  • Evidence of bleeding diathesis or coagulopathy
  • Acute bacterial or fungal infections
  • Acute exacerbation of
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulopathy
  • Acquired immune deficiency syndrome; note, however, that testing is not required for study entry.
  • Inability to undergo MRI (e.g., presence of a pacemaker)
  • Known intolerance to study medication
  • Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written
  • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment or within 5 plasma half-life of the preceding study drug, whatever is longer.
  • Pregnancy or breastfeeding
  • In case of both complete absence of intra-operative fluorescence between any of the inserted light diffusers and absence of significant surgery-associated bleedings (i.e. light transmission is detectable between at least two of the inserted light diffusers), the tumor will be classified as 'fluorescence-negative tumor'. iPDT will however be performed. Regarding efficacy evaluation, patients with fluorescence-negative tumors will be excluded from PP-, but included in the ITT-evaluation, and will be evaluated regarding safety.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Interstitial photodynamic therapy

    20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.

    Drug: 5-aminolevulinic acid

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the incidence of treatment-emergent Adverse Events (safety and tolerability) of iPDT with PD L 506 in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma.

    The incidence of treatment-emergent Adverse Events (TEAEs) of CTC grades 3, 4 and 5 within two weeks following iPDT

    Time frame: 2 weeks

Secondary outcomes

  1. Progression-free survival rate at 12 months

    Percentage of patients without tumor progression 12 months after iPDT

    Time frame: 12 months

  2. Overall survival rate at 12 months

    Percentage of patients who are alive 12 months after iPDT

    Time frame: 12 months

  3. Progression-free survival

    Time until first tumor progression

    Time frame: From date of iPDT until the date of first documented progression, up to 66 months

  4. Overall survival

    Time until death from any cause

    Time frame: From date of iPDT until the date of death from any cause, up to 66 months

  5. MGMT promoter methylation status of the patient

    Analytical results for MGMT promoter methylation status (methylated/unmethylated) in the respective tumor samples of each patient

    Time frame: Baseline

  6. Immune status of the patient

    Analytical results for immune parameters (PBMC, CD4+, CD8+) in the respective blood samples of each patient

    Time frame: Baseline, 2 days, 2 weeks after iPDT and then every 3 months, up to 66 months

  7. Results of investigator's assessment of patient's physical condition using Karnofsky performance status scale

    To determine patient's physical condition using Karnofsky performance status scale ranging from 0% (worst outcome) to 100% (best outcome)

    Time frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months

  8. Results of investigator's assessment of patient's mental condition using Mini-mental State Examination

    To determine patient's mental condition using Mini-mental State Examination scale ranging from 0 (worst outcome) to 30 (best outcome)

    Time frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months

  9. Results of investigator's assessment of patient's mental condition using National Institutes of Health Stroke Scale

    To determine patient's mental condition using National Institutes of Health Stroke Scale ranging from 0 (best outcome) to 34 (worst outcome)

    Time frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months

  10. Results of investigator's assessment of patient's condition using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Questionnaire (QLQ-C30) together with the Brain module (BN20)

    To determine patient's quality of life

    Time frame: Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months

  11. Interstitial light transmittance and fluorescence data recorded

    To determine whether correlations exist between length of OS/PFS and spectral online-monitoring measurement results (transmission and fluorescence measurements)

    Time frame: during iPDT treatment (up to 1 hour)

  12. Interstitial fluorescence data recorded

    To determine the rate of patients with fluorescence-negative tumors

    Time frame: during iPDT treatment (up to 1 hour)

  13. Percentage of cylindrical diffusor laser probes without kinks, cracks etc. before and after iPDT for patients treated under protocol versions prior to V7.0

    Assessing the safety and performance of the insertion of Cylindrical Diffusor Laser Probes into the brain for iPDT of brain tumors for patients treated under protocol versions prior to V7.0.

    Time frame: Day 0 (Treatment day), directly before and after iPDT

  14. Percentage of guiding catheters without kinks, cracks etc. before and after iPDT

    Assessing the safety and performance of the insertion of guiding catheters into the brain for iPDT of brain tumors

    Time frame: Day 0 (Treatment day), directly before and after iPDT

  15. Percentage of iPDT treatments in which the laser system works properly as planned.

    Assessing safety and performance of the laser system for iPDT of brain tumors.

    Time frame: Day 0 (Treatment day), directly after iPDT

  16. Percentage of fibers/laser ports which show a maximum deviation in the output power of less than +/-10% to the pre-defined output power of 200 mW/cm diffusor length.

    Assessing safety and performance of the combination of ML7710i laser system and Cylindrical Diffusor Laser Probes for the iPDT of brain tumors.

    Time frame: Day 0 (Treatment day), directly after iPDT

07

Study locations

3 sites
  • Uniklinik Köln
    Cologne, 50924, Germany
  • Klinikum der Universität München
    München, 81377, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Apr 2026, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Apr 1, 2019
StartActual
Sep 3, 2021
Primary completionActual
Apr 8, 2026
CompletionActual
Apr 8, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03897491
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Sep 3, 2021
Primary completion
Apr 8, 2026
Completion
Apr 8, 2026
Last update
Jun 1, 2026

Study contacts

Walter Stummer, Prof. Dr.
principal investigator · Universitätsklinikum Münster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion